JP2009526834A - タンパク質凝集の疾患の治療のための組成物および方法 - Google Patents

タンパク質凝集の疾患の治療のための組成物および方法 Download PDF

Info

Publication number
JP2009526834A
JP2009526834A JP2008554886A JP2008554886A JP2009526834A JP 2009526834 A JP2009526834 A JP 2009526834A JP 2008554886 A JP2008554886 A JP 2008554886A JP 2008554886 A JP2008554886 A JP 2008554886A JP 2009526834 A JP2009526834 A JP 2009526834A
Authority
JP
Japan
Prior art keywords
epi
disease
compound
pharmaceutical composition
inositol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008554886A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009526834A5 (https=
Inventor
ジョアン マクローリン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2009526834A publication Critical patent/JP2009526834A/ja
Publication of JP2009526834A5 publication Critical patent/JP2009526834A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2008554886A 2006-02-17 2007-02-16 タンパク質凝集の疾患の治療のための組成物および方法 Withdrawn JP2009526834A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77481806P 2006-02-17 2006-02-17
PCT/IB2007/001929 WO2007129221A2 (en) 2006-02-17 2007-02-16 Compositions comprising an epi-inositol compounds and methods for treatment of disorders of protein aggregation

Publications (2)

Publication Number Publication Date
JP2009526834A true JP2009526834A (ja) 2009-07-23
JP2009526834A5 JP2009526834A5 (https=) 2010-03-25

Family

ID=38668147

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008554886A Withdrawn JP2009526834A (ja) 2006-02-17 2007-02-16 タンパク質凝集の疾患の治療のための組成物および方法

Country Status (5)

Country Link
US (1) US20070197453A1 (https=)
EP (1) EP1993523A4 (https=)
JP (1) JP2009526834A (https=)
CA (1) CA2642647A1 (https=)
WO (1) WO2007129221A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US7985847B2 (en) 2006-05-08 2011-07-26 Biojoule Ltd. Recovery of lignin and water soluble sugars from plant materials
AU2008293139A1 (en) 2007-08-31 2009-03-05 Vertichem Corporation Lignin and other products isolated from plant material, and methods and compositions therefor
AT506535B1 (de) 2008-02-22 2010-04-15 Affiris Forschungs & Entwicklungs Gmbh Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden
US9116157B2 (en) 2010-11-05 2015-08-25 Brandeis University Ice-cleaved alpha-synuclein as a biomarker
JP6576400B2 (ja) * 2017-07-27 2019-09-18 アンリツ株式会社 移動端末試験装置とそのパラメータ変更方法
AU2020341464A1 (en) * 2019-09-05 2022-04-21 Trevena, Inc. Methods of treating epilepsy using the same
EP4694889A1 (en) * 2023-04-13 2026-02-18 Acelot, Inc. Compounds and methods for treating protein aggregation diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4454151A (en) * 1982-03-22 1984-06-12 Syntex (U.S.A.) Inc. Use of pyrrolo pyrroles in treatment of ophthalmic diseases
US4474806A (en) * 1982-05-10 1984-10-02 Merck & Co., Inc. Sulfonyl or carbonyl inositol derivatives useful as anti-inflammatory/analgesic agents
KR0185215B1 (ko) * 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
US5756541A (en) * 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
US6818430B1 (en) * 1999-06-07 2004-11-16 Hokko Chemical Industry Co., Ltd. Process for producing L-epi-2-inosose and novel process for producing epi-inositol
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
WO2002062385A2 (en) * 2001-02-06 2002-08-15 Qlt, Inc. Method to prevent vision loss
US8034803B2 (en) * 2001-02-06 2011-10-11 Qlt Inc. Photodynamic therapy of occult age-related macular degeneration
US20030181531A1 (en) * 2003-02-11 2003-09-25 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
US6599891B2 (en) * 2001-07-20 2003-07-29 Qlt Inc. Treatment of macular edema
US20040058313A1 (en) * 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
ATE458042T1 (de) * 2003-10-14 2010-03-15 Hokko Chem Ind Co Verfahren zur herstellung von scyllo-inositol
US8193250B2 (en) * 2004-10-22 2012-06-05 Mount Sinai School Of Medicine Compositions and methods for treating alzheimer's disease and related disorders and promoting a healthy nervous system
CN103301094A (zh) * 2004-11-17 2013-09-18 乔安妮·麦克劳林 用于治疗蛋白聚集疾病的含鲨肌醇衍生物的组合物和方法

Also Published As

Publication number Publication date
WO2007129221A2 (en) 2007-11-15
WO2007129221A8 (en) 2008-04-10
EP1993523A4 (en) 2009-06-10
EP1993523A2 (en) 2008-11-26
CA2642647A1 (en) 2007-11-15
WO2007129221A3 (en) 2008-03-20
US20070197453A1 (en) 2007-08-23

Similar Documents

Publication Publication Date Title
Pan et al. Sodium rutin ameliorates Alzheimer’s disease–like pathology by enhancing microglial amyloid-β clearance
JP2012214516A (ja) シロイノシトール誘導体を含む組成物およびタンパク質凝集障害を治療するための方法
Spangenberg et al. Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer’s disease model
US20100292157A1 (en) Combination Treatments for Alzheimer's Disease and Similar Diseases
Aaseth et al. Treatment strategies in Alzheimer’s disease: a review with focus on selenium supplementation
US20100173960A1 (en) The Combination of a Cyclohexanehexol and a NSAID for the Treatment of Neurodegenerative Diseases
US8859628B2 (en) Method for preventing, treating and diagnosing disorders of protein aggregation
Morroni et al. Early effects of Aβ1-42 oligomers injection in mice: Involvement of PI3K/Akt/GSK3 and MAPK/ERK1/2 pathways
JP2009526834A (ja) タンパク質凝集の疾患の治療のための組成物および方法
US20070197452A1 (en) Treatment of amyloid-related diseases
US20070111970A1 (en) Inositol compounds and uses of same in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, desposition, accumulation or persistence
KR20090026247A (ko) 단백질 응집 장애의 치료를 위한 사이클로헥산 폴리알콜 제형
Wang et al. Naturally occurring autoantibodies against Aβ oligomers exhibited more beneficial effects in the treatment of mouse model of Alzheimer's disease than intravenous immunoglobulin
JP2018534336A (ja) アルツハイマー病および関連障害を処置するための方法
Nelson Peripheral pathways to neurovascular unit dysfunction, cognitive impairment, and Alzheimer’s disease
Zhang et al. Rescue of cognitive deficits in APP/PS1 mice by accelerating the aggregation of β-amyloid peptide
US20170143769A1 (en) Human umbilical cord blood-derived monocytes for treatment of neurodegenerative diseases and disorders
CA2579188A1 (en) Treatment of amyloid-related diseases
Li et al. Bicyclol improves cognition deficits and inhibits oxidative stress-induced neuronal cell apoptosis in alzheimer’s disease via Nrf2/HO-1 pathway
JP7249433B2 (ja) 蜂毒抽出物を有効成分として含有する神経炎症疾患の予防または治療用組成物
US20220175888A1 (en) Carboxylated osteocalcin for treatment of amyloidosis or diseases associated with abnormal protein folding
Nave Plenary Talk P03: Axon–glia interactions and the control of myelination

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100201

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20110610

A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20110705